论文部分内容阅读
加入WTO对于我国的企业而言,机遇与风险同在。我国的企业如何应对加入WTO的挑战,是国人普遍关心的问题。江苏省江山制药公司是一个出口主导型的国有中型企业,出口产品是人们日常生活中常用的药品维生素C(即VC)。长期以来,在国际VC市场上,跨国公司一直占据垄断地位。五年前,当中国VC出口量在国际市场上占到一定份额时,以罗氏公司为主的跨国公司发动全球VC价格大战,试图凭其品牌、资金等方面的优势,以低于成本的价格在国
Accession to the WTO is an opportunity and risk for our country’s enterprises. How Chinese companies deal with the challenges of joining the WTO is a matter of common concern to the Chinese people. Jiangsu Jiangshan Pharmaceutical Co., Ltd. is an export-oriented state-owned medium-sized enterprise. The export products are commonly used vitamin C (ie, VC) in people’s daily lives. For a long time, in the international VC market, multinational companies have occupied a monopoly position. Five years ago, when China’s VC exports accounted for a certain share in the international market, multinational corporations dominated by Roche launched a global VC price war, attempting to lower prices by virtue of their brand, capital, and other advantages. In the country